- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01249066
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
November 26, 2010 updated by: China Medical University Hospital
AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia.
Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung, Taiwan, 404
- Recruiting
- Fang Hsin Yuan
-
Contact:
- Hsin-Yuan Fang, MD
- Phone Number: 1638 +886422052121
- Email: d93421104@ntu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Lung cancer received lobectomy in CMUH
Description
Inclusion Criteria:
- Lung cancer received operation lobectomy in CMUH
Exclusion Criteria:
- History of uremia, other malignant disease, and liver cirrhosis
- History of pneumonia and pulmonary tuberculosis
- History of long period of medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Study Registration Dates
First Submitted
November 24, 2010
First Submitted That Met QC Criteria
November 26, 2010
First Posted (Estimate)
November 29, 2010
Study Record Updates
Last Update Posted (Estimate)
November 29, 2010
Last Update Submitted That Met QC Criteria
November 26, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DMR99-IRB-096
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.Active, not recruitingAdenocarcinoma of the LungChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingEGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IVChina
-
Rambam Health Care CampusUnknownLung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
-
Meir Medical CenterUnknownAdenocarcinoma, Bronchiolo-Alveolar | Adenocarcinoma of the LungIsrael
-
Memorial Sloan Kettering Cancer CenterCompletedOligometastatic Lung AdenocarcinomaUnited States
-
Chinese PLA General HospitalUnknown
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Fujian Medical University Union HospitalWu Jieping Medical FoundationActive, not recruitingIA Lung Adenocarcinoma | Combined SegmentectomyChina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Lung AdenocarcinomaUnited States
-
Samsung Medical CenterUnknownLung Adenocarcinoma, Stage IKorea, Republic of